CVR
Chicago Rivet & Machine Co.·Industrials
10.11
1.462%(−0.15)
Market ClosedLast Updated: — ET
52W L: $8.1552W H: $15.00
CVR NEWS
seekingalpha.com
2d ago
Undercovered Dozen: CVR Energy, Greystone Housing, Conagra Brands, And More
The Undercovered Dozen series spotlights 12 lesser-covered stocks from the past week on Seeking Alpha. This week's edition covers articles published between March 27 and April 2, offering fresh investment ideas. The focus is on stocks that may offer unique opportunities due to limited analyst coverage.
seekingalpha.com
Mar 30
CVR Energy Poised To Soar
The cycle in oil refining crack spreads bottomed in Q4 2025 and has been moving up ever since. Valuation of CVR Energy is well below peers due to previous management errors, which have now been corrected. Wars in Ukraine and Iran have damaged or destroyed multiple oil refineries, which will take years to repair or replace.
prnewswire.com
Mar 24
Chicago Rivet & Machine Co. Announces Year-End Results of Operations
WARRENVILLE, Ill., March 24, 2026 /PRNewswire/ -- Chicago Rivet & Machine Co. (NYSE American: CVR) today announced audited results for the year 2025 as summarized below: CHICAGO RIVET & MACHINE CO.
seekingalpha.com
Mar 9
CVR Partners: Iran Just Made This 12% Yield Look Cheap
CVR Partners is a compelling buy, benefiting from the Iran conflict's fertilizer supply shock and soaring nitrogen prices. UAN's U.S.-based plants avoid geopolitical chokepoints, positioning the company for strong Q1 and 2026 distributions amid global disruptions. My base case estimates a 2026 forward yield of ~13% ($16/unit), with upside if supply shocks persist; the near-term price target is $150.
prnewswire.com
Feb 23
CHICAGO RIVET & MACHINE CO. DECLARES DIVIDEND
WARRENVILLE, Ill., Feb. 23, 2026 /PRNewswire/ -- Chicago Rivet & Machine Co. (NYSE American: CVR) today announced that its Board of Directors declared a quarterly cash dividend of $0.03 per share payable March 20, 2026, to all shareholders of record on March 6, 2025.
gurufocus.com
Feb 23
Gilead Sciences Expands Oncology Portfolio with Arcellx Acquisition
Gilead Sciences (GILD) is set to enhance its oncology and cell therapy capabilities by acquiring Arcellx (ACLX). This acquisition deepens their existing collabo
